Home / HFSA News / RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

 

Boehringer Ingelheim (BI) today announced results from the large, multi-national, randomized safety trial, which compared dual therapy with a novel oral anticoagulant (NOAC) to triple therapy with warfarin in non-valvular atrial fibrillation (NVAF) patients undergoing percutaneous coronary intervention (PCI) with stenting. The findings were presented in a late-breaking spotlight session at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, and simultaneously published in the New England Journal of MedicineA press release from BI with additional study details is available here.

 

Share This